跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,431 条关于
“KEYNOTE-859”
全部
1,431
临床试验
689
药物
307
机构
10
资讯
425
去年
FDA Advisory Committee Recommends Against Checkpoint Inhibitors for Certain Gastroesophageal Cancers
2年前
FDA Approves AstraZeneca and Ionis' Wainua for Hereditary ATTR Polyneuropathy
25天前
Astellas Doses First Patient in Phase 3 Study of ASP2138, a Subcutaneous Bispecific T-Cell Engager for CLDN18.2-Positive Gastric Cancer
去年
PD-L1 Expression Thresholds in Gastrointestinal Cancers Under Scrutiny for PD-1 Inhibitor Efficacy
2年前
Merck Discontinues Phase 3 Trials of Pembrolizumab in NSCLC and CSCC
2年前
KEYNOTE-789: Pembrolizumab Plus Chemotherapy Fails to Improve Survival in EGFR-Mutated NSCLC
去年
Pembrolizumab Plus Chemotherapy Improves Overall Survival in HER2-Positive Gastric Cancer
2年前
Pembrolizumab Demonstrates Sustained Survival Benefits in Advanced Melanoma After 10-Year Follow-Up
2年前
Pembrolizumab Improves Overall Survival in Clear Cell Renal Cell Carcinoma
3个月前
The Evolving Role of Biotechnology Keynote Speakers in Shaping Pharmaceutical R&D Strategy
第 1 页,共 43 页
上一页
下一页